Topic:

R&D

Latest Headlines

Latest Headlines

MSK and Atara snag an FDA 'breakthrough' tag for T cell project

Memorial Sloan Kettering Cancer Center picked up the FDA's coveted breakthrough-therapy designation for a promising T cell therapy, working with partner Atara Biotherapeutics to get it on the market for patients with complications tied to bone marrow transplants.

Japanese 3-D bioprinter startup Cyfuse raises $12M in Series B to go global

Cyfuse Biomedical is aiming to take its 3-D bioprinting technology to researchers around the world with its infusion of ¥1.4 billion ($12 million). Its bioprinter can be used to create tissue structures including cartilage and subchondral bone, tubular tissues such as blood vessels, digestive and urinary organs, and miniature livers.

Startup Akili partners with nonprofit Autism Speaks to test video game

Akili Interactive Labs has partnered with the nonprofit Autism Speaks to conduct a clinical trial of its cognitive assessment and personalized treatment video game.

Novartis looks to squelch neuro worries over its would-be cardio blockbuster

Novartis, at work on a cardio drug widely expected to bring in billions of dollars once approved, is working to tamp down concerns that the oral treatment could increase the risk of Alzheimer's disease, adding measures of brain function to an ongoing trial.

Viehbacher wades into the startup world, joining PureTech in his first post-Sanofi move

Months after a bitter exit from the top spot at Sanofi, Christopher Viehbacher is back out in public, joining Boston startup factory PureTech to help steer its portfolio of fledgling companies.

Exclusive: AstraZeneca spinning out its anti-infectives R&D unit in Waltham

Pushing through on a plan to get out of the early-stage anti-infectives R&D space, AstraZeneca is spinning out its Waltham, MA-based company into an independent biotech, a move that will have an impact on the 95 staffers remaining in the swiftly dwindling operation.

Stealthy Lyric Pharma bags $20M for its gastro drug

South San Francisco's Lyric Pharmaceuticals raised $20.4 million in first-round financing to support its work on a hush-hush gastrointestinal drug.

Ablynx gets caught in Merck KGaA's R&D retreat

A fast-changing Merck KGaA is backing away from discovery and preclinical R&D deals it set up with the antibody specialists at Ablynx. And the Belgian biotech saw its shares slide 14% today after news of the prospective breakup--included in Ablynx's annual summary--spread in the markets.

Exact Sciences beefs up sales and reimbursement efforts for colon cancer Dx

Exact Sciences is charting big plans for 2015, increasing its sales efforts and pushing for expanded coverage of its stool-based DNA colon cancer test to grab a bigger market share.

Google Ventures funds tablet for the elderly

Entrepreneur Keith Kocho is designing a smart tablet specifically for the elderly. He's been given $1 million from Google Ventures and Atlas Venture to work on the project.